Loading
Led CONVERT, which set the radiotherapy schedule for limited-stage small-cell lung cancer.
Corinne Faivre-Finn was chief investigator of CONVERT, the international trial that compared twice-daily and once-daily thoracic radiotherapy in limited-stage SCLC and confirmed twice-daily 45 Gy as the standard. She co-leads studies of radiotherapy-immunotherapy combinations in the PACIFIC and ADRIATIC era and the Christie's thoracic radiotherapy research group.
| Title | Journal | Year |
|---|---|---|
| Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) | Lancet Oncology | 2017 |
| Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial | Journal of Thoracic Oncology | 2021 |
| ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer | New England Journal of Medicine | 2024 |
Shares Alastair Greystoke, Sanjay Popat, Non-small-cell lung cancer.
Shares CONVERT, Non-small-cell lung cancer and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares ADRIATIC, CONVERT, IMRT / IGRT (modern external beam).
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.